生物制药公司Tarsus Pharmaceuticals, Inc.（股票代码：TARS）今日盘前股价大跌7.95%，尽管公司最新发布的季度业绩优于分析师预期。这一显著跌幅引发了投资者的关注。
根据公司发布的财报，截至3月31日的季度内，Tarsus Pharmaceuticals调整后每股亏损0.64美元，好于分析师平均预期的0.73美元亏损。公司营收同比大幅增长183.7%，达到7834万美元，超过分析师预期的7247万美元。尽管业绩超出预期，但公司在本季度仍录得2512万美元的亏损。
值得注意的是，Tarsus Pharmaceuticals的股价表现一直存在波动。本季度股价上涨1.1%，但今年迄今为止已下跌6.2%。分析师对该公司的前景仍保持乐观，目前的平均评级为"强力买入"，12个月目标价中位数为73.00美元。然而，过去三个月内，分析师对公司的平均盈利预测下调了约20.6%，这可能部分解释了投资者对公司长期盈利能力的担忧，从而导致了今日的股价下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.